Detalhe da pesquisa
1.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet
; 394(10216): 2271-2281, 2019 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31868632
2.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet
; 393(10184): 1948-1957, 2019 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30982686
3.
Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
Gastric Cancer
; 20(2): 358-367, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27255289
4.
New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin.
Chemotherapy
; 62(1): 62-70, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27643822
5.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Lancet Oncol
; 17(12): 1697-1708, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27776843
6.
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Lancet
; 385(9976): 1418-27, 2015 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25539730
7.
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.
Blood
; 124(5): 720-8, 2014 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24939657
8.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Lancet Haematol
; 11(2): e101-e113, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38302221
9.
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.
Hemasphere
; 7(7): e904, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37427146
10.
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
J Clin Oncol
; 40(32): 3750-3761, 2022 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35709415
11.
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.
Breast
; 66: 110-117, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36223695
12.
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study.
Leukemia
; 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38830959
13.
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
Eur J Cancer
; 49(4): 835-42, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23063354
14.
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood
; 106(2): 458-63, 2005 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15817679